Cardiovascular Adverse Events With Intravitreal Anti-Vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Clinical Trials.

ABSTRACT: Systemic safety of intravitreal anti-vascular endothelial growth factor (anti-VEGF) is a matter of debate and regular updates are necessary. To evaluate systemic adverse events (SAEs) associated with intravitreal anti-VEGF drugs compared with non-anti-VEGF treatments in patients with ocular diseases. Electronic searches were conducted in MEDLINE, Embase, and Cochrane Central Register of Controlled Trials databases from inception to July 7, 2020. Randomized clinical trials conducted in adults with retinal diseases who received intravitreal anti-VEGF drugs. Studies and treatment characteristics and outcome data were extracted and analyzed, and study quality was evaluated. Main outcomes were major cardiovascular events (MACEs) and total mortality. Secondary outcomes included nonocular hemorrh

SUBMITTER: Ngo Ntjam N 

PROVIDER: S-EPMC8050790 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature